The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis

被引:39
|
作者
Liang, Chunlian [1 ]
Li, Xiuli [1 ]
Zhang, Lin [1 ]
Cui, Dajiang [1 ]
Quan, Xiaojuan [1 ]
Yang, Weilin [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Geriatr, Sch Med, Xian 710004, Shaanxi, Peoples R China
关键词
miR-153; TGF-beta; TGFBR2; Idiopathic pulmonary fibrosis; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; LUNG FIBROSIS; EXTRACELLULAR-MATRIX; LATENT TGF-BETA-1; FIBROBLASTS; ACTIVATION; EXPRESSION; RECEPTORS; DIFFERENTIATION;
D O I
10.1016/j.yexmp.2015.07.011
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial fibrotic lung disease with an undefined etiology and no effective treatments. By binding to cell surface receptors, transforming growth factor-beta (TGF-beta) plays a pivotal role in lung fibrosis. Therefore, the screening of microRNAs (miRNAs), especially those interrupting the effects of TGF-beta, may provide information not only on the pathomechanism, but also on the treatment of this disease. In the present study, we found that miR-153 expression was dysregulated in the lungs of mice with experimental pulmonary fibrosis and TGF-beta 1 decreased miR-153 expression in pulmonary fibroblasts. Moreover, increased miR-153 levels attenuated, whereas the knock down of miR-153 promoted the pro-fibrogenic activity of TGF-beta 1, and miR-153 reduced the contractile and migratory activities of fibroblasts. In addition, TGFBR2, a transmembrane serine/threonine kinase receptor for TGF-beta, was identified as a direct target of miR-153. Furthermore, by post-transcriptional regulation of the expression of TGEBR2, phosphorylation of SMAD2/3 was also influenced by miR-153. These data suggest that miR-153 disturbs TGF-beta 1 signal transduction and its effects on fibroblast activation, acting as an anti-fibrotic element in the development of pulmonary fibrosis. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:279 / 285
页数:7
相关论文
共 50 条
  • [41] Missing out on effective care in idiopathic pulmonary fibrosis: Racial inequality in access to anti-fibrotic therapy
    Pascoe, Amy
    Smallwood, Natasha
    RESPIROLOGY, 2023, 28 (11) : 978 - 979
  • [42] The anti-fibrotic agent SMP-534 attenuates bleomycin-induced pulmonary fibrosis in hamsters
    Tsujimura, Tsuyoshi
    Ono-Kishino, Michiko
    Nagamine, Jun
    Sugaru, Eiji
    Tokunaga, Teruhisa
    Kitoh, Makoto
    Nagata, Ryu
    Nakagawa, Tsutomu
    Taiji, Mutsuo
    BIOMEDICAL RESEARCH-TOKYO, 2009, 30 (03): : 177 - 182
  • [43] Relaxin Can Mediate Its Anti-Fibrotic Effects by Targeting the Myofibroblast NLRP3 Inflammasome at the Level of Caspase-1
    Pinar, Anita A.
    Yuferov, Alexander
    Gaspari, Tracey A.
    Samuel, Chrishan S.
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [44] PULMONARY HYPERTENSION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS ON ANTI-FIBROTIC TREATMENT WITH PIRFENIDONE OR NINTEDANIB: CLINICAL EVALUATION AND PROGNOSTIC IMPACT
    Stornelli, Silvia Romana
    Lacedonia, Donato
    Scioscia, Giulia
    Simone, Filomena
    Lepore, Giorgia
    Sabato, Roberto
    Giganti, Giulio
    Ciliberti, Gianluca
    Barbaro, Maria Pia Foschino
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [45] Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
    De Biasi, Sara
    Cerri, Stefania
    Bianchini, Elena
    Gibellini, Lara
    Persiani, Elisa
    Montanari, Gloria
    Luppi, Fabrizio
    Carbonelli, Cristiano Matteo
    Zucchi, Luigi
    Bocchino, Marialuisa
    Zamparelli, Alessandro Sanduzzi
    Vancheri, Carlo
    Sgalla, Giacomo
    Richeldi, Luca
    Cossarizza, Andrea
    BMC MEDICINE, 2015, 13
  • [46] Mogroside IIIE, a Novel Anti-Fibrotic Compound, Reduces Pulmonary Fibrosis through Toll-Like Receptor 4 Pathways
    Tao, Lijun
    Yang, Jinyu
    Cao, Fengyan
    Xie, Haifeng
    Zhang, Mian
    Gong, Yanqing
    Zhang, Chaofeng
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 361 (02) : 268 - 279
  • [47] Anti-fibrotic effects of fresh and cryopreserved human amniotic membrane in a rat liver fibrosis model
    Ricci, Emanuele
    Vanosi, Graziella
    Lindenmair, Andrea
    Hennerbichler, Simone
    Peterbauer-Scherb, Anja
    Wolbank, Susanne
    Cargnoni, Anna
    Signoroni, Patrizia Bonassi
    Campagnol, Marino
    Gabriel, Christian
    Redl, Heinz
    Parolini, Ornella
    CELL AND TISSUE BANKING, 2013, 14 (03) : 475 - 488
  • [48] MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells
    Zhou, Jun
    Xie, Ming
    Shi, Ying
    Luo, Baihua
    Gong, Guanghui
    Li, Juanni
    Wang, Junpu
    Zhao, Wenjian
    Zi, Yuan
    Wu, Xiaoying
    Wen, Jifang
    ONCOLOGY REPORTS, 2015, 34 (01) : 111 - 120
  • [49] Effects of Cheonwangbosim-dan in a Mouse Model of Chronic Obstructive Pulmonary Disease: Anti-Inflammatory and Anti-Fibrotic Therapy
    Kang, Jee Hyun
    Jung, Eunhye
    Hong, Eun-Ju
    Baek, Eun Bok
    Lee, Mee-Young
    Kwun, Hyo-Jung
    APPLIED SCIENCES-BASEL, 2023, 13 (03):
  • [50] Anti-fibrotic effects of the Masson pine pollen aqueous extract on hepatic fibrosis rat model
    Cong, Tao
    Jin, Xue-Yuan
    Zhao, Lin
    Ma, Long
    Li, Rui-Sheng
    Zhao, Ping
    Guo, Chang-Jiang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (05): : 4651 - 4661